Remove DNA Remove Protein Expression Remove Trials
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Josh’s work at the Marine Biological Laboratory unlocked the potential of utilizing an endogenous protein to make a single alphabet change on RNA (RNA editing), a process that was precise, reversible and had druglike characteristics. We intended to learn from nature (genetics) and use pharmaceuticals properties to drive patient benefit.

RNA 67
article thumbnail

The Magic of Fast Feedback Loops

Codon

DNA sequencing and synthesis costs have dropped precipitously, in part, because maintaining Carlson curves became a rallying point for the field. One such opportunity, for example, is in protein expression. Learning requires trial, error, and revision. DOI: 10.62211/55gh-72ht Lead image by Ella Watkins-Dulaney.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Conversations in Drug Development Trends

Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention? Integrate Biomarkers Where Possible Biomarker integration is crucial in solid tumor clinical trials, though more research is needed before fully validated assays become the norm across solid tumor indications.

article thumbnail

The Future of Drug Discovery: Tackling the Undruggable with New Biotechnologies

DrugBank

However, the discovery of a pocket in the KRAS G12C mutation led to the development of drugs like sotorasib, showing promising results in clinical trials. Several PPI modulators have reached clinical trials, and some have even been approved for use, showcasing their potential for a wide range of diseases.

article thumbnail

The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans

Conversations in Drug Development Trends

The analysis of circulating tumor DNA (ctDNA) in a liquid biopsy can also permit genotyping and help monitor the effectiveness of chemotherapy. Proteomics Proteomics involves studying the entire set of proteins expressed in a cell or tissue.

article thumbnail

Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer

Broad Institute

Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52
article thumbnail

Radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

The Pharma Data

Fibroblast activation protein (FAP) is a cell-surface protein expressed at low levels in most normal adult tissues, but over-expressed in common cancers, particularly on cancer-associated fibroblasts that form the tumor stroma, which is essential for growth 1 ,2 ,3 ,4.